Europe and Middle East & Africa Respiratory Panel Testing Market Outlook 2031

  • The Europe and Middle East & Africa respiratory panel testing market was valued over US$ 1.6 Bn in 2020
  • It is estimated to expand at a CAGR of 5.1% from 2021 to 2031
  • The Europe and Middle East & Africa respiratory panel testing market is expected to surpass the value of US$ 3.1 Bn by the end of 2031

Analysts’ Viewpoint on Europe and Middle East & Africa Respiratory Panel Testing Market Scenario

Healthcare brands in the Europe and Middle East & Africa respiratory panel testing market are unlocking value-grab opportunities through eCommerce to keep economies running during the ongoing COVID-19 pandemic. However, several respiratory pathogens can cause nearly indistinguishable symptoms. Hence, manufacturers should develop panels that provide fast and comprehensive results with a run time of less than an hour. Quick turnaround on a broad menu of pathogens may also help clinicians make vital decisions regarding admission, isolation, and additional diagnostic testing. The high prevalence of seasonal influenza, human rhinovirus, and viral infections is fueling the demand for respiratory panel testing. High sensitivity and specificity is preferred in respiratory panels.

CE-marked Respiratory Panels Improving Patient Outcomes

Rapid and automated detection of pathogens is significantly changing in the Europe and Middle East & Africa respiratory panel testing market. There is a demand for panels that test multiple viruses and bacteria that cause respiratory tract infections. Manufacturers are increasing the availability of panels that eliminate the need for precise measuring or pipetting. Fast turnaround time is preferred in respiratory panel testing.

High sensitivity and specificity in respiratory panel testing is helping to boost product sales. Panels based on TGA (Therapeutic Goods Administration)-certified multiplex PCR (polymerase chain reaction) systems are boosting the credibility of healthcare brands. FDA-cleared and CE marked panels are helping to improve patient outcomes.

Request a sample to get extensive insights into the Respiratory Panel Testing Market

FDA De Novo-authorized Panels Gain Demand for Diagnosis of COVID-19 Pathogens

SARS-CoV-2 has become a top concern for patients and healthcare practitioners. Companies in the Europe and Middle East & Africa respiratory panel testing market are increasing the availability of products to reduce the stress of clinicians. However, several respiratory pathogens can cause nearly indistinguishable symptoms. Hence, companies are increasing R&D investment to develop FDA De Novo authorized panels that help clinicians to quickly diagnose respiratory infections, including COVID-19, RSV, influenza, and the likes.

Manufacturers in the Europe and Middle East & Africa respiratory panel testing market are developing products that use a syndromic approach to accurately detect and identify the pathogens most commonly associated with respiratory infections. These panels are being used in combination with rapid respiratory PCR test results to enable better-informed diagnosis and treatment of patients.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Multiplex PCR-based Respiratory Viral Panels Provide Prompt Results

PCR-based panels are increasingly replacing viral culture to detect pathogens. However, companies in the Europe and Middle East & Africa respiratory panel testing market should increase the availability of products to support pathogen detection, which is useful for clinicians and clinical microbiologists. PCR-based panels are emerging as an alternative to viral culture, since the latter is slow and labor-intensive. These panels are gaining popularity for the detection of viral nucleic acids and provide prompt results with high sensitivity & specificity.

Manufacturers are boosting the production for multiplex PCR-based respiratory viral panels for the test of influenza, respiratory syncytial virus (RSV), and rhinovirus, among others.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Respiratory Panel Testing Market

High Prevalence of Lower RTIs Fueling Demand for Respiratory Panel Testing

The high prevalence of both self-limiting upper respiratory tract infections (RTIs) and more severe lower RTIs such as bronchitis & pneumonitis is fueling the demand for respiratory panel testing. It has been found that lower RTIs are a major cause for hospitalization, morbidity, and mortality in infants and the elderly. In order to reduce their treatment cost, respiratory panel testing is emerging as an effective strategy.

Nasopharyngeal Swabs & Home Testing Fulfill Convenience Needs of Individuals

Companies in the Europe and Middle East & Africa respiratory panel testing market are capitalizing on incremental opportunities, since PCR-based panels are a preferred option for the evaluation of severely immunocompromised patients with respiratory symptoms. The high prevalence of parainfluenza, human metapneumovirus (hMPV), and adenovirus is driving the demand for respiratory panel products.

In order to tap revenue opportunities through eCommerce, manufacturers in the Europe and Middle East & Africa respiratory panel testing market are developing products that help to collect specimens through nasopharyngeal swab. The growing trend of home testing provided by labs is another driver contributing to market growth. The Europe and Middle East & Africa respiratory panel testing market is expanding due to product demand for testing human rhinovirus and human metapneumovirus, among others.

Europe and Middle East & Africa Respiratory Panel Testing Market: Overview

  • Respiratory panel testing is a diagnostic testing panel used for the detection of pathogens in the respiratory tract. The pathogen can be a virus, bacteria, and other organism, which affects the nose, throat, and lungs, and causes breathing issues.
  • Respiratory panel testing detects various viruses including adenovirus, flu, coronavirus, and other deadly viruses. The panel requires a single sample to run various tests for diagnosis of viruses and bacteria. Various testing panels offered by the key players are rapid and automatic for faster detection of the various viruses, such as SARS-CoV-2, in a short time.

Europe and Middle East & Africa Respiratory Panel Testing Market: Key Drivers

  • Rise in prevalence of hospital-acquired infections, increase in cases of coronavirus outbreak, and surge in asthma & COPD cases are projected to drive the respiratory panel testing market in EMEA. Availability of novel and cost-efficient respiratory disease testing devices, kits, software, and consumables will aid early diagnosis of these diseases. According to the European Centre for Disease Prevention and Control (ECDC) data, 3.1 million to 4.6 million patients acquire hospital-acquired infections every year.
  • Launch of innovative COVID-19 kits & products and collaborations among key players are the other factors propelling the market in EMEA. In September 2020, DiaSorin received CE Mark for the addition of saliva specimens for use with the Simplexa COVID-19 Direct assay. In February 2020, altona Diagnostics GmbH launched the RealStar SARS-CoV-2 RT-PCR Kit 1.0. The assay is based on real-time RT-PCR technology for the detection of SARS-CoV-2 (previously 2019-nCoV), which is the causative agent of coronavirus disease 2019 (COVID-19). In July 2017, Anatolia Geneworks launched Bosphore Respiratory Pathogens Panel Kit v1. These strategic steps taken by key players are expected to augment the market during the forecast period.

Market Segmentation: Europe and Middle East & Africa Respiratory Panel Testing Market

  • In terms of specimen type, the respiratory panel testing market in EMEA has been bifurcated into viruses and bacteria. The viruses segment has been split into adenovirus, SARS-CoV-2, RSV, human metapneumo virus, rhinovirus/enterovirus, parainfluenza, virus flu A, coronavirus, flu B, HIN1 2009, and others.
  • Majority of countries struggling with viral infections are in Central and Eastern Europe. The Czech Republic, a central European country with 10.7 million population, is the worst hit, where cases have risen sharply in the past few weeks. This factor is likely to boost the growth of the viruses segment during the forecast period. The bacteria segment has been segregated into mycoplasma pneumoniae, chlamydophila pneumonia, bordetella pertussis, bordetella parapertussis, and others.
  • Based on panel type, the respiratory panel testing market in EMEA has been classified into syndromic full multiplex panel, and low plex panel. The syndromic full multiplex panel segment accounted for the largest market share in 2020, as syndromic full multiplex panel methods are usually used for the simultaneous detection of two or more target pathogenic DNA or RNA molecules by using several specific primers in a single PCR reaction. Furthermore, syndromic molecular testing has been integrated into routine clinical care, either to provide diagnostic, epidemiological, or patient management information. These factors are anticipated to fuel the growth of the segment in the next few years.
  • In terms of end-user, the respiratory panel testing market in EMEA has been divided into hospital point of-care testing, ref laboratories, hospitals, and others. Increase in incidence of respiratory diseases leads to rise in hospital admissions, which is expected to drive the segment during the forecast period.
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The respiratory panel testing market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: Europe and Middle East & Africa Respiratory Panel Testing Market

  • Europe dominated the Respiratory panel testing market in EMEA in 2020, accounting for 85.5% share. Rise in prevalence of respiratory diseases, increase in the geriatric population, and technological advancements in respiratory panel testing are projected to boost the growth of the market in the region during the forecast period. Moreover, increase in incidence of viral infections is anticipated to fuel the growth of the Respiratory panel testing market in Europe in the next few years. For instance, the U.K., Russia, France, Spain, and Italy reported the highest number of confirmed COVID-19 cases during the pandemic.
  • Germany is expected to dominate the respiratory panel testing market in Europe in terms of market share during the forecast period. The country is considered to have robust and well-established medical diagnostics market. Outbreak of COVID-19 placed an enormous public health burden on the country, which is expected to drive the demand for testing panel in the market. In November 2021, the U.K. reported 9,637,190 confirmed coronavirus cases, which is likely to propel the respiratory panel testing market in the country.

Major Players

  • The respiratory panel testing market report concludes with the company profiles section, which includes key information about major players in the Respiratory panel testing market in EMEA
  • Leading players analyzed in the report include
    • F. Hoffmann-La Roche Ltd.
    • bioMerieux SA
    • Medline Industries, Inc.
    • Becton
    • Dickinson & Company
    • altona Diagnostics GmbH
    • CerTest Biotec S.L.
    • Anatolia Geneworks
    • Seegene, Inc.
    • DiaSorin S.p.A. (Luminex)
    • QIAGEN
    • Biocartis
  • Each of these players has been profiled in the respiratory panel testing market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Europe and Middle East & Africa Respiratory Panel Testing Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 1.6 Bn

Market Forecast Value in 2031

US$ 3.1 Bn

Growth Rate (CAGR)

5.1%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competitive Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • By Specimen Type
    • Viruses
      • Adenovirus
      • Severe Acute Respiratory Syndrome Coronavirus 2
      • RSV
      • Human Metapneumovirus
      • Rhinovirus/Enterovirus
      • Parainfluenza Virus
      • Flu A
      • Coronavirus
      • Flu B
      • H1N12009
      • Others
    • Bacteria
      • Mycoplasma Pneumoniae
      • Chlamydophila Pneumonia
      • Bordetella Pertussis
      • Bordetella Parapertussis
  • By Panel Type
    • Syndromic Full Multiplex Panel
    • Low Flex Panel
  • By End-user
    • Hospital Point-of-Care Testing
    • Ref Laboratories
    • Hospitals
    • Others

Regions Covered

  • Europe
  • Middle East & Africa

Countries Covered

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Benelux
  • Poland
  • Sweden
  • Denmark
  • Finland
  • Norway
  • Switzerland
  • Austria
  • Rest of Europe
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Companies Profiled

  • F. Hoffmann-La Roche Ltd.
  • bioMerieux SA
  • Medline Industries, Inc.
  • Becton, Dickinson & Company
  • altona Diagnostics GmbH
  • CerTest Biotec S.L.
  • Anatolia Geneworks
  • Seegene, Inc.
  • DiaSorin S.p.A. (Luminex)
  • QIAGEN
  • Biocartis
  • Other Prominent Players

Customization Scope

Available upon request

Pricing

Available upon request

Europe and Middle East & Africa Respiratory Panel Testing Market – Scope of Report

TMR’s report on the respiratory panel testing market in Europe and Middle East & Africa studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides the overall revenue of the respiratory panel testing market in Europe and Middle East & Africa for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the respiratory panel testing market in Europe and Middle East & Africa for the forecast period.

The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the respiratory panel testing market in Europe and Middle East & Africa.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts also employed a combination of top-down and bottom-up approaches to study various phenomena in the respiratory panel testing market in Europe and Middle East & Africa.

The report comprises an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the respiratory panel testing market in Europe and Middle East & Africa. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the respiratory panel testing market in Europe and Middle East & Africa. The next section of the respiratory panel testing market report highlights the USPs, which includes, COVID-19 pandemic impact on industry (value chain and short/mid/long term impact), and key industry events (mergers, acquisitions, partnerships, etc.) across Europe and Middle East & Africa.

The report delves into the competitive landscape of the respiratory panel testing market in Europe and Middle East & Africa. Key players operating in the respiratory panel testing market in Europe and Middle East & Africa have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the respiratory panel testing market in report.

Key Questions Answered in Europe and Middle East & Africa Respiratory Panel Testing Market Report

  • What are the sales/revenue generated by respiratory panel testing across Europe and Middle East & Africa during the forecast period?
  • What are the key trends in the respiratory panel testing market in Europe and Middle East & Africa?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which segment will have the highest revenue by 2031 and which segment will grow at the highest CAGR during the forecast period?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Strengths and weaknesses of major players (2019–2020)
  • Competitive analysis of major players (2019–2020)

Europe and Middle East & Africa Respiratory Panel Testing Market – Research Objectives and Research Approach

The comprehensive report on the respiratory panel testing market in Europe and Middle East & Africa begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the respiratory panel testing market in Europe and Middle East & Africa. It is followed by market introduction, market dynamics, and an overview of the respiratory panel testing market in Europe and Middle East & Africa, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the respiratory panel testing market in Europe and Middle East & Africa.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key product manufacturers has been mapped to ascertain the size of the respiratory panel testing market in Europe and Middle East & Africa in terms of value. The forecast presented here assesses the total revenue generated in the respiratory panel testing market in Europe and Middle East & Africa. In order to provide an accurate forecast, we initiated by sizing up the current respiratory panel testing market in Europe and Middle East & Africa with the help of the parent market.

The report analyzes the respiratory panel testing market in Europe and Middle East & Africa in terms of specimen type, panel type, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2031 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the respiratory panel testing market in Europe and Middle East & Africa.

Europe and Middle East & Africa Respiratory Panel Testing Market – Segmentation

Specimen Type
  • Viruses
    • Adenovirus
    • Severe Acute Respiratory Syndrome
    • RSV
    • Human Metapneumovirus
    • Rhinovirus/Enterovirus
    • Parainfluenza Virus
    • Flu A
    • Coronavirus
    • Flu B
    • HIN1 2009
    • Others
  • Bacteria
    • Mycoplasma Pneumoniae
    • Chlamydophila Pneumonia
    • Bordetella Pertussis
    • Bordetella Parapertussis
Panel Type
  • Syndromic Full Multiplex Panel
  • Low Plex Panel
End-user
  • Hospital Point-of-Care testing
  • Ref Laboratories
  • Hospitals
  • Others
Region
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Finland
    • Norway
    • Denmark
    • Benelux
    • Switzerland
    • Poland
    • Rest of Europe
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Europe and Middle East & Africa Respiratory Panel Testing Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, 2018–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)

    5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Specimen Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

        6.3.1. Viruses

            6.3.1.1. Adenovirus

            6.3.1.2. Severe Acute Respiratory Syndrome

            6.3.1.3. RSV

            6.3.1.4. Human Metapneumovirus

            6.3.1.5. Rhinovirus/Enterovirus

            6.3.1.6. Parainfluenza Virus

            6.3.1.7. Flu A

            6.3.1.8. Others

        6.3.2. Bacteria

            6.3.2.1. Mycoplasma Pneumoniae

            6.3.2.2. Chlamydophila Pneumonia

    6.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type

7. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Panel Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

        7.3.1. Syndromic Full Multiplex Panel

        7.3.2. Low Plex Panel

    7.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Panel Type

8. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        8.3.1. Hospital Point-of-Care testing

        8.3.2. Reference Labs

        8.3.3. Hospitals

        8.3.4. Others

    8.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by End-user

9. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Region

        9.2.1. Europe

        9.2.2. Middle East & Africa

    9.3. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Country/Region

10. Europe Respiratory Panel Testing Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

        10.2.1. Viruses

            10.2.1.1. Adenovirus

            10.2.1.2. Severe Acute Respiratory Syndrome

            10.2.1.3. RSV

            10.2.1.4. Human Metapneumovirus

            10.2.1.5. Rhinovirus/Enterovirus

            10.2.1.6. Parainfluenza Virus

            10.2.1.7. Flu A

            10.2.1.8. Others

        10.2.2. Bacteria

            10.2.2.1. Mycoplasma Pneumoniae

            10.2.2.2. Chlamydophila Pneumonia

    10.3. Market Value Forecast, by Panel Type, 2017–2031

        10.3.1. Syndromic Full Multiplex Panel

        10.3.2. Low Plex Panel

    10.4. Market Value Forecast, by End-user, 2017–2031

        10.4.1. Hospital Point-of-Care testing

        10.4.2. Ref Laboratories

        10.4.3. Hospitals

        10.4.4. Others

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. Germany

            10.5.1.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.1.1.1. Viruses

                    10.5.1.1.1.1. Adenovirus

                    10.5.1.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.1.1.1.3. RSV

                    10.5.1.1.1.4. Human Metapneumovirus

                    10.5.1.1.1.5. Rhinovirus/Enterovirus

                    10.5.1.1.1.6. Parainfluenza Virus

                    10.5.1.1.1.7. Flu A

                    10.5.1.1.1.8. Others

                10.5.1.1.2. Bacteria

                    10.5.1.1.2.1. Mycoplasma Pneumoniae

                    10.5.1.1.2.2. Chlamydophila Pneumonia

            10.5.1.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.1.2.1. Syndromic Full Multiplex Panel

                10.5.1.2.2. Low Plex Panel

            10.5.1.3. Market Value Forecast, by End-user, 2017–2031

                10.5.1.3.1. Hospital Point-of-Care testing

                10.5.1.3.2. Ref Laboratories

                10.5.1.3.3. Hospitals

                10.5.1.3.4. Others

        10.5.2. U.K.

            10.5.2.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.2.1.1. Viruses

                    10.5.2.1.1.1. Adenovirus

                    10.5.2.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.2.1.1.3. RSV

                    10.5.2.1.1.4. Human Metapneumovirus

                    10.5.2.1.1.5. Rhinovirus/Enterovirus

                    10.5.2.1.1.6. Parainfluenza Virus

                    10.5.2.1.1.7. Flu A

                    10.5.2.1.1.8. Others

                10.5.2.1.2. Bacteria

                    10.5.2.1.2.1. Mycoplasma Pneumoniae

                    10.5.2.1.2.2. Chlamydophila Pneumonia

            10.5.2.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.2.2.1. Syndromic Full Multiplex Panel

                10.5.2.2.2. Low Plex Panel

            10.5.2.3. Market Value Forecast, by End-user, 2017–2031

                10.5.2.3.1. Hospital Point-of-Care testing

                10.5.2.3.2. Ref Laboratories

                10.5.2.3.3. Hospitals

                10.5.2.3.4. Others

        10.5.3. France

            10.5.3.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.3.1.1. Viruses

                    10.5.3.1.1.1. Adenovirus

                    10.5.3.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.3.1.1.3. RSV

                    10.5.3.1.1.4. Human Metapneumovirus

                    10.5.3.1.1.5. Rhinovirus/Enterovirus

                    10.5.3.1.1.6. Parainfluenza Virus

                    10.5.3.1.1.7. Flu A

                    10.5.3.1.1.8. Others

                10.5.3.1.2. Bacteria

                    10.5.3.1.2.1. Mycoplasma Pneumoniae

                    10.5.3.1.2.2. Chlamydophila Pneumonia

            10.5.3.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.3.2.1. Syndromic Full Multiplex Panel

                10.5.3.2.2. Low Plex Panel

            10.5.3.3. Market Value Forecast, by End-user, 2017–2031

                10.5.3.3.1. Hospital Point-of-Care testing

                10.5.3.3.2. Ref Laboratories

                10.5.3.3.3. Hospitals

                10.5.3.3.4. Others

        10.5.4. Italy

            10.5.4.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.4.1.1. Viruses

                    10.5.4.1.1.1. Adenovirus

                    10.5.4.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.4.1.1.3. RSV

                    10.5.4.1.1.4. Human Metapneumovirus

                    10.5.4.1.1.5. Rhinovirus/Enterovirus

                    10.5.4.1.1.6. Parainfluenza Virus

                    10.5.4.1.1.7. Flu A

                    10.5.4.1.1.8. Others

                10.5.4.1.2. Bacteria

                    10.5.4.1.2.1. Mycoplasma Pneumoniae

                    10.5.4.1.2.2. Chlamydophila Pneumonia

            10.5.4.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.4.2.1. Syndromic Full Multiplex Panel

                10.5.4.2.2. Low Plex Panel

            10.5.4.3. Market Value Forecast, by End-user, 2017–2031

                10.5.4.3.1. Hospital Point-of-Care testing

                10.5.4.3.2. Ref Laboratories

                10.5.4.3.3. Hospitals

                10.5.4.3.4. Others

        10.5.5. Spain

            10.5.5.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.5.1.1. Viruses

                    10.5.5.1.1.1. Adenovirus

                    10.5.5.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.5.1.1.3. RSV

                    10.5.5.1.1.4. Human Metapneumovirus

                    10.5.5.1.1.5. Rhinovirus/Enterovirus

                    10.5.5.1.1.6. Parainfluenza Virus

                    10.5.5.1.1.7. Flu A

                    10.5.5.1.1.8. Others

                10.5.5.1.2. Bacteria

                    10.5.5.1.2.1. Mycoplasma Pneumoniae

                    10.5.5.1.2.2. Chlamydophila Pneumonia

            10.5.5.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.5.2.1. Syndromic Full Multiplex Panel

                10.5.5.2.2. Low Plex Panel

            10.5.5.3. Market Value Forecast, by End-user, 2017–2031

                10.5.5.3.1. Hospital Point-of-Care testing

                10.5.5.3.2. Ref Laboratories

                10.5.5.3.3. Hospitals

                10.5.5.3.4. Others

        10.5.6. Benelux

            10.5.6.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.6.1.1. Viruses

                    10.5.6.1.1.1. Adenovirus

                    10.5.6.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.6.1.1.3. RSV

                    10.5.6.1.1.4. Human Metapneumovirus

                    10.5.6.1.1.5. Rhinovirus/Enterovirus

                    10.5.6.1.1.6. Parainfluenza Virus

                    10.5.6.1.1.7. Flu A

                    10.5.6.1.1.8. Others

                10.5.6.1.2. Bacteria

                    10.5.6.1.2.1. Mycoplasma Pneumoniae

                    10.5.6.1.2.2. Chlamydophila Pneumonia

            10.5.6.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.6.2.1. Syndromic Full Multiplex Panel

                10.5.6.2.2. Low Plex Panel

            10.5.6.3. Market Value Forecast, by End-user, 2017–2031

                10.5.6.3.1. Hospital Point-of-Care testing

                10.5.6.3.2. Ref Laboratories

                10.5.6.3.3. Hospitals

                10.5.6.3.4. Others

        10.5.7. Poland

            10.5.7.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.7.1.1. Viruses

                    10.5.7.1.1.1. Adenovirus

                    10.5.7.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.7.1.1.3. RSV

                    10.5.7.1.1.4. Human Metapneumovirus

                    10.5.7.1.1.5. Rhinovirus/Enterovirus

                    10.5.7.1.1.6. Parainfluenza Virus

                    10.5.7.1.1.7. Flu A

                    10.5.7.1.1.8. Others

                10.5.7.1.2. Bacteria

                    10.5.7.1.2.1. Mycoplasma Pneumoniae

                    10.5.7.1.2.2. Chlamydophila Pneumonia

            10.5.7.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.7.2.1. Syndromic Full Multiplex Panel

                10.5.7.2.2. Low Plex Panel

            10.5.7.3. Market Value Forecast, by End-user, 2017–2031

                10.5.7.3.1. Hospital Point-of-Care testing

                10.5.7.3.2. Ref Laboratories

                10.5.7.3.3. Hospitals

                10.5.7.3.4. Others

        10.5.8. Sweden

            10.5.8.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.8.1.1. Viruses

                    10.5.8.1.1.1. Adenovirus

                    10.5.8.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.8.1.1.3. RSV

                    10.5.8.1.1.4. Human Metapneumovirus

                    10.5.8.1.1.5. Rhinovirus/Enterovirus

                    10.5.8.1.1.6. Parainfluenza Virus

                    10.5.8.1.1.7. Flu A

                    10.5.8.1.1.8. Others

                10.5.8.1.2. Bacteria

                    10.5.8.1.2.1. Mycoplasma Pneumoniae

                    10.5.8.1.2.2. Chlamydophila Pneumonia

            10.5.8.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.8.2.1. Syndromic Full Multiplex Panel

                10.5.8.2.2. Low Plex Panel

            10.5.8.3. Market Value Forecast, by End-user, 2017–2031

                10.5.8.3.1. Hospital Point-of-Care testing

                10.5.8.3.2. Ref Laboratories

                10.5.8.3.3. Hospitals

                10.5.8.3.4. Others

        10.5.9. Denmark

            10.5.9.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.9.1.1. Viruses

                    10.5.9.1.1.1. Adenovirus

                    10.5.9.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.9.1.1.3. RSV

                    10.5.9.1.1.4. Human Metapneumovirus

                    10.5.9.1.1.5. Rhinovirus/Enterovirus

                    10.5.9.1.1.6. Parainfluenza Virus

                    10.5.9.1.1.7. Flu A

                    10.5.9.1.1.8. Others

                10.5.9.1.2. Bacteria

                    10.5.9.1.2.1. Mycoplasma Pneumoniae

                    10.5.9.1.2.2. Chlamydophila Pneumonia

            10.5.9.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.9.2.1. Syndromic Full Multiplex Panel

                10.5.9.2.2. Low Plex Panel

            10.5.9.3. Market Value Forecast, by End-user, 2017–2031

                10.5.9.3.1. Hospital Point-of-Care testing

                10.5.9.3.2. Ref Laboratories

                10.5.9.3.3. Hospitals

                10.5.9.3.4. Others

        10.5.10. Finland

            10.5.10.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.10.1.1. Viruses

                    10.5.10.1.1.1. Adenovirus

                    10.5.10.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.10.1.1.3. RSV

                    10.5.10.1.1.4. Human Metapneumovirus

                    10.5.10.1.1.5. Rhinovirus/Enterovirus

                    10.5.10.1.1.6. Parainfluenza Virus

                    10.5.10.1.1.7. Flu A

                    10.5.10.1.1.8. Others

                10.5.10.1.2. Bacteria

                    10.5.10.1.2.1. Mycoplasma Pneumoniae

                    10.5.10.1.2.2. Chlamydophila Pneumonia

            10.5.10.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.10.2.1. Syndromic Full Multiplex Panel

                10.5.10.2.2. Low Plex Panel

            10.5.10.3. Market Value Forecast, by End-user, 2017–2031

                10.5.10.3.1. Hospital Point-of-Care testing

                10.5.10.3.2. Ref Laboratories

                10.5.10.3.3. Hospitals

                10.5.10.3.4. Others

        10.5.11. Norway

            10.5.11.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.11.1.1. Viruses

                    10.5.11.1.1.1. Adenovirus

                    10.5.11.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.11.1.1.3. RSV

                    10.5.11.1.1.4. Human Metapneumovirus

                    10.5.11.1.1.5. Rhinovirus/Enterovirus

                    10.5.11.1.1.6. Parainfluenza Virus

                    10.5.11.1.1.7. Flu A

                    10.5.11.1.1.8. Others

                10.5.11.1.2. Bacteria

                    10.5.11.1.2.1. Mycoplasma Pneumoniae

                    10.5.11.1.2.2. Chlamydophila Pneumonia

            10.5.11.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.11.2.1. Syndromic Full Multiplex Panel

                10.5.11.2.2. Low Plex Panel

            10.5.11.3. Market Value Forecast, by End-user, 2017–2031

                10.5.11.3.1. Hospital Point-of-Care testing

                10.5.11.3.2. Ref Laboratories

                10.5.11.3.3. Hospitals

                10.5.11.3.4. Others

        10.5.12. Switzerland

            10.5.12.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.12.1.1. Viruses

                    10.5.12.1.1.1. Adenovirus

                    10.5.12.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.12.1.1.3. RSV

                    10.5.12.1.1.4. Human Metapneumovirus

                    10.5.12.1.1.5. Rhinovirus/Enterovirus

                    10.5.12.1.1.6. Parainfluenza Virus

                    10.5.12.1.1.7. Flu A

                    10.5.12.1.1.8. Others

                10.5.12.1.2. Bacteria

                    10.5.12.1.2.1. Mycoplasma Pneumoniae

                    10.5.12.1.2.2. Chlamydophila Pneumonia

            10.5.12.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.12.2.1. Syndromic Full Multiplex Panel

                10.5.12.2.2. Low Plex Panel

            10.5.12.3. Market Value Forecast, by End-user, 2017–2031

                10.5.12.3.1. Hospital Point-of-Care testing

                10.5.12.3.2. Ref Laboratories

                10.5.12.3.3. Hospitals

                10.5.12.3.4. Others

        10.5.13. Austria

            10.5.13.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.13.1.1. Viruses

                    10.5.13.1.1.1. Adenovirus

                    10.5.13.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.13.1.1.3. RSV

                    10.5.13.1.1.4. Human Metapneumovirus

                    10.5.13.1.1.5. Rhinovirus/Enterovirus

                    10.5.13.1.1.6. Parainfluenza Virus

                    10.5.13.1.1.7. Flu A

                    10.5.13.1.1.8. Others

                10.5.13.1.2. Bacteria

                    10.5.13.1.2.1. Mycoplasma Pneumoniae

                    10.5.13.1.2.2. Chlamydophila Pneumonia

            10.5.13.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.13.2.1. Syndromic Full Multiplex Panel

                10.5.13.2.2. Low Plex Panel

            10.5.13.3. Market Value Forecast, by End-user, 2017–2031

                10.5.13.3.1. Hospital Point-of-Care testing

                10.5.13.3.2. Ref Laboratories

                10.5.13.3.3. Hospitals

                10.5.13.3.4. Others

        10.5.14. Rest of Europe

            10.5.14.1. Market Value Forecast, by Specimen Type, 2017–2031

                10.5.14.1.1. Viruses

                    10.5.14.1.1.1. Adenovirus

                    10.5.14.1.1.2. Severe Acute Respiratory Syndrome

                    10.5.14.1.1.3. RSV

                    10.5.14.1.1.4. Human Metapneumovirus

                    10.5.14.1.1.5. Rhinovirus/Enterovirus

                    10.5.14.1.1.6. Parainfluenza Virus

                    10.5.14.1.1.7. Flu A

                    10.5.14.1.1.8. Others

                10.5.14.1.2. Bacteria

                    10.5.14.1.2.1. Mycoplasma Pneumoniae

                    10.5.14.1.2.2. Chlamydophila Pneumonia

            10.5.14.2. Market Value Forecast, by Panel Type, 2017–2031

                10.5.14.2.1. Syndromic Full Multiplex Panel

                10.5.14.2.2. Low Plex Panel

            10.5.14.3. Market Value Forecast, by End-user, 2017–2031

                10.5.14.3.1. Hospital Point-of-Care testing

                10.5.14.3.2. Ref Laboratories

                10.5.14.3.3. Hospitals

                10.5.14.3.4. Others

    10.6. Market Attractiveness Analysis

        10.6.1. By Specimen Type

        10.6.2. By Panel Type

        10.6.3. By End-user

        10.6.4. By Country/Sub-region

11. Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

        11.2.1. Viruses

            11.2.1.1. Adenovirus

            11.2.1.2. Severe Acute Respiratory Syndrome

            11.2.1.3. RSV

            11.2.1.4. Human Metapneumovirus

            11.2.1.5. Rhinovirus/Enterovirus

            11.2.1.6. Parainfluenza Virus

            11.2.1.7. Flu A

            11.2.1.8. Others

        11.2.2. Bacteria

            11.2.2.1. Mycoplasma Pneumoniae

            11.2.2.2. Chlamydophila Pneumonia

    11.3. Market Value Forecast, by Panel Type, 2017–2031

        11.3.1. Syndromic Full Multiplex Panel

        11.3.2. Low Plex Panel

    11.4. Market Value Forecast, by End-user, 2017–2031

        11.4.1. Hospital Point-of-Care testing

        11.4.2. Ref Laboratories

        11.4.3. Hospitals

        11.4.4. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. GCC Countries

            11.5.1.1. Market Value Forecast, by Specimen Type, 2017–2031

                11.5.1.1.1. Viruses

                    11.5.1.1.1.1. Adenovirus

                    11.5.1.1.1.2. Severe Acute Respiratory Syndrome

                    11.5.1.1.1.3. RSV

                    11.5.1.1.1.4. Human Metapneumovirus

                    11.5.1.1.1.5. Rhinovirus/Enterovirus

                    11.5.1.1.1.6. Parainfluenza Virus

                    11.5.1.1.1.7. Flu A

                    11.5.1.1.1.8. Others

                11.5.1.1.2. Bacteria

                    11.5.1.1.2.1. Mycoplasma Pneumoniae

                    11.5.1.1.2.2. Chlamydophila Pneumonia

            11.5.1.2. Market Value Forecast, by Panel Type, 2017–2031

                11.5.1.2.1. Syndromic Full Multiplex Panel

                11.5.1.2.2. Low Plex Panel

            11.5.1.3. Market Value Forecast, by End-user, 2017–2031

                11.5.1.3.1. Hospital Point-of-Care testing

                11.5.1.3.2. Ref Laboratories

                11.5.1.3.3. Hospitals

                11.5.1.3.4. Others

        11.5.2. South Africa

            11.5.2.1. Market Value Forecast, by Specimen Type, 2017–2031

                11.5.2.1.1. Viruses

                    11.5.2.1.1.1. Adenovirus

                    11.5.2.1.1.2. Severe Acute Respiratory Syndrome

                    11.5.2.1.1.3. RSV

                    11.5.2.1.1.4. Human Metapneumovirus

                    11.5.2.1.1.5. Rhinovirus/Enterovirus

                    11.5.2.1.1.6. Parainfluenza Virus

                    11.5.2.1.1.7. Flu A

                    11.5.2.1.1.8. Others

                11.5.2.1.2. Bacteria

                    11.5.2.1.2.1. Mycoplasma Pneumoniae

                    11.5.2.1.2.2. Chlamydophila Pneumonia

            11.5.2.2. Market Value Forecast, by Panel Type, 2017–2031

                11.5.2.2.1. Syndromic Full Multiplex Panel

                11.5.2.2.2. Low Plex Panel

            11.5.2.3. Market Value Forecast, by End-user, 2017–2031

                11.5.2.3.1. Hospital Point-of-Care testing

                11.5.2.3.2. Ref Laboratories

                11.5.2.3.3. Hospitals

                11.5.2.3.4. Others

        11.5.3. Rest of Middle East & Africa

            11.5.3.1. Market Value Forecast, by Specimen Type, 2017–2031

                11.5.3.1.1. Viruses

                    11.5.3.1.1.1. Adenovirus

                    11.5.3.1.1.2. Severe Acute Respiratory Syndrome

                    11.5.3.1.1.3. RSV

                    11.5.3.1.1.4. Human Metapneumovirus

                    11.5.3.1.1.5. Rhinovirus/Enterovirus

                    11.5.3.1.1.6. Parainfluenza Virus

                    11.5.3.1.1.7. Flu A

                    11.5.3.1.1.8. Others

                11.5.3.1.2. Bacteria

                    11.5.3.1.2.1. Mycoplasma Pneumoniae

                    11.5.3.1.2.2. Chlamydophila Pneumonia

            11.5.3.2. Market Value Forecast, by Panel Type, 2017–2031

                11.5.3.2.1. Syndromic Full Multiplex Panel

                11.5.3.2.2. Low Plex Panel

            11.5.3.3. Market Value Forecast, by End-user, 2017–2031

                11.5.3.3.1. Hospital Point-of-Care testing

                11.5.3.3.2. Ref Laboratories

                11.5.3.3.3. Hospitals

                11.5.3.3.4. Others

12. Competitive Landscape

    12.1. Market Player –Competition Matrix (By Tier and Size of companies)

    12.2. Company Profiles (2020)

        12.2.1. F. Hoffmann-La Roche Ltd.

            12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.1.2. Product Portfolio

            12.2.1.3. Financial Overview

            12.2.1.4. Strategic Overview

            12.2.1.5. SWOT Analysis

        12.2.2. bioMerieux SA

            12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.2.2. Product Portfolio

            12.2.2.3. Financial Overview

            12.2.2.4. Strategic Overview

            12.2.2.5. SWOT Analysis

        12.2.3. Medline Industries, Inc.

            12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.3.2. Product Portfolio

            12.2.3.3. Strategic Overview

            12.2.3.4. SWOT Analysis

        12.2.4. Becton, Dickinson & Company

            12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.4.2. Product Portfolio

            12.2.4.3. Financial Overview

            12.2.4.4. Strategic Overview

            12.2.4.5. SWOT Analysis

        12.2.5. altona Diagnostics GmbH

            12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.5.2. Product Portfolio

            12.2.5.3. Strategic Overview

            12.2.5.4. SWOT Analysis

        12.2.6. CerTest Biotec S.L.

            12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.6.2. Product Portfolio

            12.2.6.3. Strategic Overview

            12.2.6.4. SWOT Analysis

        12.2.7. Anatolia Geneworks

            12.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.7.2. Product Portfolio

            12.2.7.3. Strategic Overview

            12.2.7.4. SWOT Analysis

        12.2.8. Seegene, Inc.

            12.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.8.2. Product Portfolio

            12.2.8.3. Strategic Overview

            12.2.8.4. SWOT Analysis

        12.2.9. DiaSorin S.p.A. (Luminex)

            12.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.9.2. Product Portfolio

            12.2.9.3. Financial Overview

            12.2.9.4. Strategic Overview

            12.2.9.5. SWOT Analysis

        12.2.10. QIAGEN

            12.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.10.2. Product Portfolio

            12.2.10.3. Financial Overview

            12.2.10.4. Strategic Overview

            12.2.10.5. SWOT Analysis

        12.2.11. Biocartis

            12.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.11.2. Product Portfolio

            12.2.11.3. Strategic Overview

            12.2.11.4. SWOT Analysis

List of Tables

Table 01: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 02: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 03: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 04: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 05: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 06: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 07: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 08: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 09: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 10: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 11: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 12: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 13: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 14: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 15: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 16: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 17: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 18: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 19: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 20: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 21: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 22: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 23: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 24: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 25: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 26: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 27: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 28: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 29: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 30: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 31: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 32: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 33: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 34: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 35: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 36: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 37: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 38: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 39: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 40: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 41: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 42: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 43: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 44: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 45: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 46: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 47: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 48: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 49: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 50: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 51: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 52: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 53: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 54: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 55: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 56: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 57: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 58: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 59: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 60: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 61: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 62: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 63: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 64: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 65: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 66: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 67: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 68: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 69: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 70: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 71: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 72: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 73: Poland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 74: Poland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 75: Poland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

List of Figures

Figure 01: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by Panel Specimen Type, 2020

Figure 03: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by Specimen Type, 2020

Figure 04: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by End-user, 2020

Figure 05: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by Region, 2020

Figure 06: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 07: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 08: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Viruses, 2017–2031

Figure 09: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Bacteria, 2017–2031

Figure 10: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 11: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 12: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Syndromic Full Multiplex Panel, 2017–2031

Figure 13: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Low Plex Panel, 2017–2031

Figure 14: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 15: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 16: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Hospital Point-of-Care Testing, 2017–2031

Figure 17: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Ref Laboratories, 2017–2031

Figure 18: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Hospitals, 2017–2031

Figure 19: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Others, 2017–2031

Figure 20: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Analysis, 2020 and 2031

Figure 21: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by Region, 2021–2031

Figure 22: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 23: Europe Respiratory Panel Testing Market Value Share, by Country/Sub-region, 2020–2031

Figure 24: Europe Respiratory Panel Testing Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 25: Europe Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 26: Europe Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 27: Europe Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 28: Europe Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 29: Europe Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 30: Europe Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 31: Germany Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 32: Germany Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 33: Germany Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 34: Germany Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 35: Germany Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 36: Germany Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 37: U.K. Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 38: U.K. Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 39: U.K. Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 40: U.K. Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 41: U.K. Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 42: U.K. Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 43: France Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 44: France Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 45: France Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 46: France Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 47: France Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 48: France Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 49: Italy Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 50: Italy Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 51: Italy Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 52: Italy Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 53: Italy Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 54: Italy Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 55: Spain Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 56: Spain Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 57: Spain Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 58: Spain Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 59: Spain Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 60: Spain Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 61: Sweden Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 62: Sweden Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 63: Sweden Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 64: Sweden Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 65: Sweden Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 66: Sweden Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 67: Denmark Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 68: Denmark Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 69: Denmark Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 70: Denmark Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 71: Denmark Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 72: Denmark Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 73: Finland Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 74: Finland Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 75: Finland Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Europe And Middle East & Africa Respiratory Panel Testing Market